Literature DB >> 2491766

Fetal lung maturation: the combined use of corticosteroids and thyrotropin-releasing hormone.

W J Morales1, W F O'Brien, J L Angel, R A Knuppel, S Sawai.   

Abstract

The purpose of this randomized study was to evaluate whether the combined use of corticosteroids and thyrotropin-releasing hormone would enhance fetal lung maturation to a greater degree than would corticosteroids alone. The study was restricted to patients under 34 weeks' gestation with a lecithin/sphingomyelin (L/S) ratio less than 2.0. The patients were randomized into a study group receiving intravenous thyrotropin-releasing hormone along with intramuscular corticosteroids over 48 hours and a control group receiving only corticosteroids. Patients undelivered 1 week after the onset of therapy underwent a repeat amniocentesis to document changes in the L/S ratio. In those patients delivering within 1 week of therapy, the neonatal clinical course was established by two investigators blinded to the antenatal therapy. Compared with the control group, the group receiving antenatal corticosteroids plus thyrotropin-releasing hormone showed a greater post-therapy increase in L/S ratio, fewer respirator days, and a lower incidence of bronchopulmonary dysplasia. The results of this study suggest that the combined use of corticosteroids and thyrotropin-releasing hormone results in enhanced fetal pulmonic maturation superior to that achieved with corticosteroids alone.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2491766

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  4 in total

Review 1.  Current perspectives on the drug treatment of neonatal respiratory distress syndrome.

Authors:  D G Sweet; H L Halliday
Journal:  Paediatr Drugs       Date:  1999 Jan-Mar       Impact factor: 3.022

Review 2.  Fetal drug therapy.

Authors:  M I Evans; P G Pryde; A Reichler; M Bardicef; M P Johnson
Journal:  West J Med       Date:  1993-09

3.  Antenatal lung maturation--should we all be using thyrotropin-releasing hormone?

Authors:  N M Fisk; M J Peek
Journal:  Eur J Pediatr       Date:  1995       Impact factor: 3.183

Review 4.  Thyrotropin-releasing hormone added to corticosteroids for women at risk of preterm birth for preventing neonatal respiratory disease.

Authors:  Caroline A Crowther; Zarko Alfirevic; Shanshan Han; Ross R Haslam
Journal:  Cochrane Database Syst Rev       Date:  2013-11-21
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.